版本:
中国

BRIEF-Aurinia Pharma presents voclosporin remission data

June 16 Aurinia Pharmaceuticals Inc:

* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017

* Aurinia Pharmaceuticals Inc - no unexpected safety signals nor adverse events were observed and voclosporin was generally well-tolerated

* Aurinia Pharmaceuticals - there were no electrolyte changes in treatment groups, mean blood pressure was similar across treatment groups through 48 weeks

* Aurinia Pharmaceuticals - voclosporin treated groups showed statistically significant improvement over control group in speed, rates of complete, partial remission

* Aurinia Pharma- voclosporin treated groups demonstrated statistically significant improvement over control group in speed, rates of complete, partial remission Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐